UNSPSC 51182703: Glipizide/metformin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182703 Glipizide/metformin is a Commodity code nominally describing pharmaceutical products for diabetes management, but the recent state and local procurement activity tagged under this code does not reflect that scope. Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually — emergency-response and harm-reduction supplies bearing no relationship to the code's stated pharmaceutical category. The mismatch suggests either a data-entry error in the county's procurement system or a jurisdictional classification practice that does not align the UNSPSC code to the actual goods being solicited. The opportunity did show standard state and local procurement mechanics: electronic bid submission through the county's e-Procurement Portal, unit-cost pricing, E-Verify and drug-free workplace compliance requirements, a two-year initial term with one-year renewal option, and insurance requirements including workers' compensation and commercial general liability.

The single recent opportunity in the record is Seminole County, Florida's IFB 60459723LAS, with a response deadline of July 26, 2023 (noting that this date predates the current posting date of June 30, 2026, suggesting data inconsistency in the source). Delivery is quarterly to the Seminole County Community Health Building in Sanford, with all shipping included in bid pricing. The procurement shows potential FEMA funding, introducing federal compliance obligations such as adherence to the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside or disadvantaged-enterprise designation appears in the record. The code shows minimal recent activity relevant to the stated pharmaceutical scope; this summary reflects the single tagged opportunity but flags the fundamental mismatch between the code's name and the work actually being solicited.